Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2

1. Campone, M.
2. Im, S.-A.
3. Iwata, H.
4. Clemons, M.
5. Ito, Y.
6. Awada, A.
7. Chia, S.
8. Jagiełło-Gruszfeld, A.
9. Pistilli, B.
10. Tseng, L.-M.
11. Hurvitz, S.
12. Masuda, N.
13. Cortés, J.
14. De Laurentiis, M.
15. Arteaga, C.L.
16. Jiang, Z.
17. Jonat, W.
18. Le Mouhaër, S.
19. Sankaran, B.
20. Bourdeau, L.
21. El-Hashimy, M.
22. Sellami, D.
23. Baselga, J.